Insider Transactions in Q3 2023 at Pliant Therapeutics, Inc. (PLRX)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
20,050
-9.33%
|
$401,000
$20.01 P/Share
|
|
Aug 04
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,791
+3.93%
|
$17,582
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Open market or private sale
|
Direct |
1,800
+0.87%
|
$36,000
$20.0 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,800
+0.86%
|
$3,600
$2.08 P/Share
|
|
Aug 03
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
13,069
-5.96%
|
$261,380
$20.0 P/Share
|
|
Jul 20
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
4,755
-7.29%
|
$80,835
$17.55 P/Share
|
|
Jul 17
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
12,778
-16.39%
|
$230,004
$18.01 P/Share
|
|
Jul 17
2023
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
17,937
-7.56%
|
$322,866
$18.01 P/Share
|
|
Jul 17
2023
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
22,321
-11.78%
|
$401,778
$18.01 P/Share
|
|
Jul 17
2023
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
70,150
-17.02%
|
$1,262,700
$18.01 P/Share
|
|
Jul 17
2023
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,771
-8.84%
|
$355,878
$18.01 P/Share
|
|
Jul 14
2023
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
27,187
+25.85%
|
-
|
|
Jul 14
2023
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,156
+12.91%
|
-
|
|
Jul 14
2023
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+18.75%
|
-
|
|
Jul 14
2023
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
38,750
+14.76%
|
-
|
|
Jul 14
2023
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
137,500
+25.01%
|
-
|